<DOC>
	<DOCNO>NCT00943410</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high-energy x-ray kill tumor cell . Trastuzumab may make tumor cell sensitive radiation therapy . Giving trastuzumab together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study side effect well give trastuzumab together external beam radiation therapy work treat woman stage III stage IV breast cancer .</brief_summary>
	<brief_title>Trastuzumab External Beam Radiation Therapy Treating Women With Stage III Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tolerability trastuzumab ( Herceptin® ) concurrent external beam radiotherapy woman HER2-overexpressing stage III IV breast cancer . Secondary - Determine pathologic response rate patient treat regimen . - Determine locoregional recurrence rate ( site first recurrence recurrence ) time locoregional recurrence patient treat regimen . - Determine time local progression patient ( deem non-surgical candidate ) treat regimen . OUTLINE : This multicenter study . Patients receive trastuzumab IV 30-90 minute week 5 week . Patients also undergo external beam radiotherapy daily 5 day week 5 week . Three week completion trastuzumab radiotherapy , patient undergo surgical evaluation . Patients deem surgical candidate undergo surgery . Patients deem non-surgical candidate continue receive trastuzumab external beam radiotherapy 2 additional week . After completion study therapy , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* invasive primary carcinoma breast fineneedle aspiration , core needle biopsy , incisional biopsy Excisional biopsy allow Stage III IV disease ( clinical radiographic stag ) , include follow : Any T N2 disease ( metastasis ipsilateral axillary lymph node fix one another structure ) N3 disease ( metastasis ipsilateral internal mammary lymph node ) T4 , N disease Inflammatory disease Supraclavicular and/or infraclavicular adenopathy Distant metastasis measurable disease breast lymph node HER2overexpressing tumor Measurable evaluable disease Residual locoregional disease completion neoadjuvant chemotherapy OR locoregional recurrent disease Synchronous bilateral primary cancer allow provide serious two cancer meet stag criterion Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify WBC &gt; 2,000/mm^3 Platelet count &gt; 50,000/mm^3 Hemoglobin &gt; 11 g/dL Negative pregnancy test Fertile patient must use effective contraception Radionucleotide ventriculography/LVEF normal OR ≤ 10 % asymptomatic decline baseline completion neoadjuvant chemotherapy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy breast regional lymph node Concurrent participation neoadjuvant chemotherapy clinical trial allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>